Use of inhibitors of protein kinase C epsilon to treat pain

Details Use of inhibitors of protein kinase C epsilon to treat pain Use of inhibitors of protein kinase C epsilon to treat pain

1999-07-06

2002-04-23

Russel, Jeffrey E. (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S009200, C514S016700, C514S238200, C514S247000, C514S455000, C514S459000, C514S475000, C514S510000, C514S544000

Reexamination Certificate

active

06376467

ABSTRACT:

BACKGROUND
For those who experience it, as well as for their families, communities and employers, pain is more than a minor inconvenience—it is a serious physical, emotional, social and economic burden. Because more than two million people in the United States alone are incapacitated by chronic pain on any given day (T. M. Jessell & D. D. Kelly, Pain and Analgesia in P
RINCIPLES OF
N
EURAL
S
CIENCE
, 3
rd
edition (E. R. Kandel, J. H. Schwartz, T. M. Jessell, ed., 1991)), the number of people and entities bearing these burdens is quite large.
Unfortunately, current treatments for pain are only partially effective, and many also cause debilitating or dangerous side effects. For example, non-steroidal anti-inflammatory drugs (“NSAIDs”) such as aspirin, ibuprofen and indomethacin are moderately effective against inflammatory pain but they are also renal toxins, and high doses tend to cause gastrointestinal irritation, ulceration, bleeding and confusion. Patients treated with opioids frequently experience confusion, and long-term opioid use is associated with tolerance and dependence. Local anesthetics such as lidocaine and mixelitine simultaneously inhibit pain and cause loss of normal sensation. Thus, there is a need for safe and effective treatments for pain.
Enhanced understanding of the molecular basis of pain should aid the development of pain medications. Pain is a particularly challenging subject because it is a perception based on signals received from the environment and transmitted and interpreted by the nervous system. Noxious stimuli such as heat and touch cause specialized sensory receptors in the skin to send signals to the central nervous system (“CNS”). This process is called nociception, and the peripheral sensory neurons that mediate it are nociceptors. Depending on the strength of the signal from the nociceptor(s) and the abstraction and elaboration of that signal by the CNS, a person may or may not experience a noxious stimulus as painful.
While pain is not enjoyable, it is crucial—without it, we would be oblivious to many environmental dangers. When our perception of pain is properly calibrated to the intensity of the stimulus, pain serves its intended protective function. However, certain types of tissue damage cause a phenomenon, known as hyperalgesia or pronociception, in which relatively innocuous stimuli are perceived as intensely painful because the person's pain thresholds have been lowered. Both inflammation and nerve damage can induce hyperalgesia. Thus, persons afflicted with inflammatory conditions, such as sunburn, osteoarthritis, colitis, carditis, dermatitis, myositis, neuritis, collagen vascular diseases (which include rheumatoid arthritis and lupus) and the like, often experience enhanced sensations of pain. Similarly, trauma, surgery, amputation, abscess, causalgia, collagen vascular diseases, demyelinating diseases, trigeminal neuralgia, cancer, chronic alcoholism, stroke, thalamic pain syndrome, diabetes, herpes infections, acquired immune deficiency syndrome (“AIDS”), toxins and chemotherapy cause nerve injuries that result in excessive pain. Apparently, the reduced pain thresholds characteristic of hyperalgesia are due to alterations in the way that nociceptors adjacent to the inflammation or damaged nerves respond to noxious stimuli. If the mechanisms by which nociceptors transduce external signals under normal and hyperalgesic conditions were better understood, it might be possible to identify processes unique to hyperalgesia that, when interrupted, could inhibit the lowering of the pain threshold and thereby lessen the amount of pain experienced. Since such a treatment for chronic pain would act at the level of the sensory afferent neurons, it would bypass the problems associated with drugs that act on the CNS. If the treatment incapacitated a transduction pathway specific to nociceptors and/or not involved in mediating other signals, then the potential for treatment-induced side effects would be small. The present invention provides such a method of alleviating pain.
SUMMARY OF THE INVENTION
The present invention is a method of lessening pain comprising administering to a subject in need thereof, an effective amount of an inhibitor of the s isozyme of protein kinase C (“PKC&egr;”). A second aspect of the invention is the use of a PKC&egr; inhibitor to decrease hyperalgesia, preferably without impairing nociception. Inhibitors that are selective for PKC&egr; are preferred, and local administration of the inhibitor is preferred. A third aspect of the invention is a method of identifying compounds that modulate pain comprising selecting a test compound that modulates the activity of PKC&egr; and administering said test compound to a subject to determine whether pain is modulated. A fourth aspect of the invention is a pharmaceutical composition comprising an inhibitor of PKC&egr; and an analgesic agent that is not an inhibitor of PKC&egr;. This invention is well suited to the treatment of subjects having acute or chronic pain caused by neuropathic or inflammatory conditions.


REFERENCES:
patent: 5141957 (1992-08-01), Jiang et al.
patent: 5204370 (1993-04-01), Jiang et al.
patent: 5216014 (1993-06-01), Jiang et al.
patent: 5270310 (1993-12-01), Bell et al.
patent: 5292737 (1994-03-01), Defauw
patent: 5344841 (1994-09-01), Jiang et al.
patent: 5360818 (1994-11-01), Jiang et al.
patent: 5432198 (1995-07-01), Jagdmann, Jr.
patent: 5519003 (1996-05-01), Mochly-Rosen et al.
patent: 5565454 (1996-10-01), Cincotta
patent: 5716968 (1998-02-01), Driedger et al.
patent: 5783405 (1998-07-01), Mochly-Rosen et al.
patent: 5800385 (1998-09-01), Demopolus et al.
patent: 5919826 (1999-07-01), Caruso
patent: WO 97/15575 (1997-05-01), None
Wyngaarden et al, eds. Cecil Textbook of Medicine, 19th ed. Philadelphia: W.B. Saunders Co. vol. 2, pp. 2244-2245, 1992.*
Gekeler et al. Effects of the selective bisindolylmaleimide . . . Br. J. Cancer, vol. 74, No. 6, pp. 897-905, Sep. 1996.*
Schaap et al. Expression, Purification, and Characterization . . . J. Biol. Chem. vol. 265, No. 13, pp. 7301-7307, May 5, 1990.*
Ahlgren et al., “Increased Responsiveness of Sensory Neurons in the Saphenous Nerve of the Streptozotocin-Diabetic Rat,”Journal of Neurophysiology, 68(6):2077-2085, (1992).
Ahlgren et al., “Mechanical Hyperalgesia in Streptozotocin-Diabetic Rats,”Neuroscience, 52(4):1049-1055, (1993).
Aley et al., “Different Mechanisms Mediate Development and Expression of Tolerance and Dependence for Peripheral &mgr;-Opioid Antinociception in Rat,”The Journal of Neuroscience, 17(20):8018-8023, (1997).
Aley et al., “Vincristine Hyperalgesia in the Rat: A Model of Painful Vincristine Neuropathy in Humans,”Neuroscience, 73(1):259-265, (1996).
Baccaglini et al., “Some rat sensory neurons in culture express characteristics of differentiated pain sensory cells,”Proc. Natl. Acad. Sci. USA, 80:594-598, (1983).
Bjorkman, “Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol,”Acta Anaesthesiol. Scand., 39(103):2-44, (1995).
Choi et al., “Effect of adrenergic receptor activation on post-herpetic neuralgia pain and sensory disturbances,”Pain, 69:55-63, (1997).
England et al., “PGE2modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade,”Journal of Physiology, 495(2):429-440, (1996).
Eriksson et al., “Effect of Epinephrine Infusion on Chest Pain in Syndrome X in the Absence of Signs of Myocardial Ischemia,”Am. J. Cardiol., 75:241-245, (1995).
Ferreira et al., “Interleukin-1&bgr; as a potent hyperalgesic agent antagonized by a tripeptide analogue,”Nature, 334:698-700, (1988).
Gold et al., “Co-Expression of Nociceptor Properties in Dorsal Root Ganglion Neurons from the Adult Rat in-vitro,”Neuroscience, 71(1):265-275, (1996).
Gold et al., “Hyperalgesic agents increase a tetrodotoxin-resistant Na+current in nociceptors,”Proc. Natl. Acad. Sci. USA, 93:1108-1112, (1996).
Goodnight et al., “Selective Involvement of Protein Kinase C Isozymes in Differentiatio

Affiliated with

Also associated with

Rating

Use of inhibitors of protein kinase C epsilon to treat pain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of inhibitors of protein kinase C epsilon to treat pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of protein kinase C epsilon to treat pain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2927415